TY - JOUR
T1 - Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4−/− Mouse
AU - Krishnan, Anuradha
AU - Katsumi, Tomohiro
AU - Guicciardi, Maria E.
AU - Azad, Adiba I.
AU - Ozturk, Nazli B.
AU - Trussoni, Christy E.
AU - Gores, Gregory J.
N1 - Funding Information:
Supported by NIH grants DK124182 (G.J.G.) and P30DK084567 (Optical Microscopy Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology), the PSC Partners Seeking a Cure Foundation (M.E.G.), the Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund for PSC, and the Mayo Clinic .
Publisher Copyright:
© 2020 American Society for Investigative Pathology
PY - 2020/6
Y1 - 2020/6
N2 - The tumor necrosis factor–related apoptosis-inducing ligand (TRAIL; TNFSF10) receptor (TR) is a pro-apoptotic receptor whose contribution to chronic cholestatic liver disease is unclear. Herein, we examined TRAIL receptor signaling in a mouse model of cholestatic liver injury. TRAIL receptor-deficient (Tnsf10 or Tr−/−) mice were crossbred with ATP binding cassette subfamily B member 4–deficient (Abcb4−/−, alias Mdr2−/−) mice. Male and female wild-type, Tr−/−, Mdr2−/−, and Tr−/−Mdr2−/− mice were assessed for liver injury, fibrosis, and ductular reactive (DR) cells. Macrophage subsets were examined by high-dimensional mass cytometry (time-of-flight mass cytometry). Mdr2−/− and Tr−/−Mdr2−/− mice had elevated liver weights and serum alanine transferase values. However, fibrosis was primarily periductular in Mdr2−/− mice, compared with extensive bridging fibrosis in Tr−/−Mdr2−/− mice. DR cell population was greatly expanded in the Tr−/−Mdr2−/− versus Mdr2−/− mice. The expanded DR cell population in Tr−/−Mdr2−/− mice was due to decreased cell loss by apoptosis and not enhanced proliferation. As assessed by time-of-flight mass cytometry, total macrophages were more abundant in Tr−/−Mdr2−/− versus Mdr2−/− mice, suggesting the DR cell population promotes macrophage-associated hepatic inflammation. Inhibition of monocyte-derived recruited macrophages using the CCR2/CCR5 antagonist cenicriviroc in the Mdr2−/− mice resulted in further expansion of the DR cell population. In conclusion, genetic deletion of TRAIL receptor increased the DR cell population, macrophage accumulation, and hepatic fibrosis in the Mdr2−/− model of cholestasis.
AB - The tumor necrosis factor–related apoptosis-inducing ligand (TRAIL; TNFSF10) receptor (TR) is a pro-apoptotic receptor whose contribution to chronic cholestatic liver disease is unclear. Herein, we examined TRAIL receptor signaling in a mouse model of cholestatic liver injury. TRAIL receptor-deficient (Tnsf10 or Tr−/−) mice were crossbred with ATP binding cassette subfamily B member 4–deficient (Abcb4−/−, alias Mdr2−/−) mice. Male and female wild-type, Tr−/−, Mdr2−/−, and Tr−/−Mdr2−/− mice were assessed for liver injury, fibrosis, and ductular reactive (DR) cells. Macrophage subsets were examined by high-dimensional mass cytometry (time-of-flight mass cytometry). Mdr2−/− and Tr−/−Mdr2−/− mice had elevated liver weights and serum alanine transferase values. However, fibrosis was primarily periductular in Mdr2−/− mice, compared with extensive bridging fibrosis in Tr−/−Mdr2−/− mice. DR cell population was greatly expanded in the Tr−/−Mdr2−/− versus Mdr2−/− mice. The expanded DR cell population in Tr−/−Mdr2−/− mice was due to decreased cell loss by apoptosis and not enhanced proliferation. As assessed by time-of-flight mass cytometry, total macrophages were more abundant in Tr−/−Mdr2−/− versus Mdr2−/− mice, suggesting the DR cell population promotes macrophage-associated hepatic inflammation. Inhibition of monocyte-derived recruited macrophages using the CCR2/CCR5 antagonist cenicriviroc in the Mdr2−/− mice resulted in further expansion of the DR cell population. In conclusion, genetic deletion of TRAIL receptor increased the DR cell population, macrophage accumulation, and hepatic fibrosis in the Mdr2−/− model of cholestasis.
UR - http://www.scopus.com/inward/record.url?scp=85084707737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084707737&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2020.02.013
DO - 10.1016/j.ajpath.2020.02.013
M3 - Article
C2 - 32240619
AN - SCOPUS:85084707737
SN - 0002-9440
VL - 190
SP - 1284
EP - 1297
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 6
ER -